EA202091513A1 - Вакцины против вируса гепатита b (hbv) и их применение - Google Patents

Вакцины против вируса гепатита b (hbv) и их применение

Info

Publication number
EA202091513A1
EA202091513A1 EA202091513A EA202091513A EA202091513A1 EA 202091513 A1 EA202091513 A1 EA 202091513A1 EA 202091513 A EA202091513 A EA 202091513A EA 202091513 A EA202091513 A EA 202091513A EA 202091513 A1 EA202091513 A1 EA 202091513A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hbv
virus
application
vaccines against
against hepatitis
Prior art date
Application number
EA202091513A
Other languages
English (en)
Inventor
Даниель Бодан
Хелен Хортон
Жан-Марк Эдмон Фернан Мари Нефс
Соумитра Рой
Дорин Де Потер
Original Assignee
Янссен Сайенсиз Айрлэнд Анлимитед Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Сайенсиз Айрлэнд Анлимитед Компани filed Critical Янссен Сайенсиз Айрлэнд Анлимитед Компани
Priority claimed from PCT/IB2018/060259 external-priority patent/WO2019123252A1/en
Publication of EA202091513A1 publication Critical patent/EA202091513A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Описаны полинуклеотиды, кодирующие ядерный антиген и полимеразный антиген вируса гепатита B (HBV), и связанные с ними комбинации. Также описаны векторы, такие как ДНК-плазмиды или вирусные векторы, экспрессирующие ядерный и полимеразный антигены HBV, и иммуногенные композиции, содержащие векторы экспрессии. Также описаны способы индукции иммунного ответа на HBV или лечения HBV-индуцированного заболевания, особенно у людей с хронической HBV-инфекцией, с помощью иммуногенных композиций.
EA202091513A 2017-12-19 2018-12-18 Вакцины против вируса гепатита b (hbv) и их применение EA202091513A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607426P 2017-12-19 2017-12-19
PCT/IB2018/060259 WO2019123252A1 (en) 2017-12-19 2018-12-18 Hepatitis b virus (hbv) vaccines and uses thereof

Publications (1)

Publication Number Publication Date
EA202091513A1 true EA202091513A1 (ru) 2020-09-09

Family

ID=66815720

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091513A EA202091513A1 (ru) 2017-12-19 2018-12-18 Вакцины против вируса гепатита b (hbv) и их применение

Country Status (2)

Country Link
US (2) US11021692B2 (ru)
EA (1) EA202091513A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
BR112019011661A2 (pt) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. Composições e métodos para aumentar expressão de gene
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
US11021692B2 (en) * 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
WO2019143949A2 (en) 2018-01-19 2019-07-25 Synthetic Genomics, Inc. Induce and enhance immune responses using recombinant replicon systems
WO2021067181A1 (en) * 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
CA3188801A1 (en) 2020-07-08 2022-01-13 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
EP4367241A1 (en) 2021-07-09 2024-05-15 GlaxoSmithKline Intellectual Property (No.3) Limited Use of oligonucleotides for individuals with renal impairment

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
DE3377363D1 (en) 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0165942A1 (en) 1983-12-23 1986-01-02 Monash University PRODUCTION OF HUMAN INTERFERON-$g(a)
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
JPH04503301A (ja) 1988-12-01 1992-06-18 ザ　トラスティーズ　オブ　ザ　ユニバーシティ　オブ　ノース　カロライナ 合成インターロイキン―６
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5246921A (en) 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
DE69431665T2 (de) 1993-08-02 2003-08-21 Scripps Research Inst Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
DE19712889A1 (de) 1997-03-27 1998-10-01 Bosch Gmbh Robert Verfahren und Vorrichtung zur Ermittlung einer den Systemdruck in einem Bremskreis beschreibenden Größe
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
IL132103A0 (en) 1997-04-03 2001-03-19 Eletrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
EP0991426B2 (fr) 1997-06-30 2007-03-28 Institut Gustave Roussy Procede de transfert d'acide nucleique dans le muscle strie
US5958060A (en) 1998-01-02 1999-09-28 General Electric Company Method and apparatus for clock control and synchronization
JP2003505114A (ja) 1998-07-13 2003-02-12 ジェネトロニクス、インコーポレーテッド パルス電場による皮膚および筋肉を標的とした遺伝子治療
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
JP2002537828A (ja) 1999-03-10 2002-11-12 フォゲン リミティド 細胞への物質のデリバリー
US20040213805A1 (en) 1999-10-12 2004-10-28 Verheije Monique Helene Deletions in arterivirus replicons
JP4647870B2 (ja) 1999-11-24 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｈｂｖ／ｈｃｖウイルス様粒子
AU2001290642A1 (en) 2000-09-07 2002-03-22 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
US6538922B1 (en) 2000-09-27 2003-03-25 Sandisk Corporation Writable tracking cells
CN100537773C (zh) 2000-11-23 2009-09-09 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
EP1363660A4 (en) 2001-02-01 2006-06-21 Univ Johns Hopkins HIGHER MOLECULAR VACCINE BASED ON AUTOMPLICATIVE RNA, SUICIDE DNA OR UNDNA DNA VECTOR, WHICH LINKS ANTIGEN WITH A POLYPEPTIDE WHICH PROMOTES THE PRESENTATION OF THE ANTIGEN
WO2002062959A2 (en) 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Hepatitis b virus treatment
EP1278382B1 (en) 2001-07-19 2007-02-14 Telefonaktiebolaget LM Ericsson (publ) Method and apparatus for solving number portability in origin
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US6943015B2 (en) 2002-12-12 2005-09-13 Ilya Frolov Large scale production of packaged alphavirus replicons
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
AU2004257214B2 (en) 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
ES2559828T3 (es) 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
US20050070700A1 (en) 2003-09-30 2005-03-31 Matthias Giese Equine arteritis virus vaccine
SG136133A1 (en) 2004-03-08 2007-10-29 Ichor Medical Systems Inc Ca U Improved apparatus for electrically mediated delivery of therapeutic agents
WO2006085983A2 (en) 2004-07-09 2006-08-17 University Of North Carolina At Chapel Hill Viral adjuvants
NZ574047A (en) * 2006-06-06 2012-01-12 Melbourne Health Determining the potential of a Hepatitis B variant to exibit antiviral resistance
EP2057268B1 (en) 2006-08-14 2014-08-13 Postech Foundation A dna vaccine for curing chronic hepatitis b and a method of preparing same
KR100841732B1 (ko) 2006-08-14 2008-06-27 포항공과대학교 산학협력단 만성 ｂ형 간염의 치료를 위한 ｄｎａ 백신 및 그의 제조방법
US20120121650A1 (en) 2006-08-18 2012-05-17 Johnston Robert E Chimeric Virus Vaccines
CN102614528B (zh) 2006-08-18 2014-02-26 箭头研究公司 用于体内递送多核苷酸的多缀合物
WO2008048632A1 (en) 2006-10-17 2008-04-24 Vgx Pharmaceuticals, Inc. Electroporation devices and methods of using same for electroporation of cells in mammals
WO2008073303A2 (en) 2006-12-07 2008-06-19 Switchgear Genomics Transcriptional regulatory elements of biological pathways, tools, and methods
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
US7850977B2 (en) 2007-06-21 2010-12-14 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
US20110110974A1 (en) 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
JP5897464B2 (ja) 2009-08-07 2016-03-30 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． Ｈｂｖ感染を治療するための組成物
ES2647662T3 (es) 2009-12-31 2017-12-26 Medigen, Inc. Vacunas de ADN infeccioso frente al virus chikungunya
SI2539451T1 (sl) 2010-02-24 2016-04-29 Arrowhead Research Corporation Sestavki za ciljano dostavo sirna
LT2590676T (lt) 2010-07-06 2016-10-25 Glaxosmithkline Biologicals Sa Viriono tipo išnešiojančios dalelės, skirtos besireplikuojančioms rnr molekulėms
EP2590670B1 (en) 2010-07-06 2017-08-23 GlaxoSmithKline Biologicals SA Methods of raising an immune response by delivery of rna
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
EP2655621B1 (en) 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
PT2672992T (pt) 2011-02-11 2020-07-27 Univ Pennsylvania Molécula de ácidos nucleicos codificando proteína nuclear do vírus da hepatite b e vacina compreendendo a mesma
EP2672991B1 (en) 2011-02-12 2017-07-19 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
KR20230156804A (ko) 2011-06-28 2023-11-14 이노비오 파마수티컬즈, 인크. 최소 침습 피부 전기천공 장치
JP6165723B2 (ja) 2011-06-30 2017-07-19 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
US9956343B2 (en) 2012-12-13 2018-05-01 Panasonic Healthcare Holdings Co., Ltd. Pharmaceutical injection device
WO2014170493A2 (en) 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
WO2015024669A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Combination vaccine
WO2016020538A1 (en) 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
KR102586707B1 (ko) 2014-10-01 2023-10-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
CN107223130A (zh) 2014-11-13 2017-09-29 日内瓦大学 作为疫苗载体的三片段沙粒病毒
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
US11559570B2 (en) 2015-05-15 2023-01-24 CureVac SE Prime-boost regimens involving administration of at least one mRNA construct
CN107921117B (zh) 2015-06-10 2022-06-07 霍欧奇帕生物科技有限公司 Hpv疫苗
EP3331554B1 (en) 2015-08-03 2022-05-11 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
CN108779472B (zh) 2015-11-04 2022-09-09 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
IL296595A (en) 2016-03-28 2022-11-01 Ichor Medical Systems Inc Method and device for administering medical substances
EP3439696A4 (en) 2016-04-06 2019-12-25 University of Washington THERAPEUTIC VACCINE AGAINST THE HEPATITIS B VIRUS (HBV) USING THE HBV CORE ANTIGEN
US10538786B2 (en) 2016-04-13 2020-01-21 Janssen Pharmaceuticals, Inc. Recombinant arterivirus replicon systems and uses thereof
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
KR20190082226A (ko) 2016-10-17 2019-07-09 신테틱 제노믹스, 인코포레이티드. 재조합 바이러스 레플리콘 시스템 및 그의 용도
BR112019011661A2 (pt) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. Composições e métodos para aumentar expressão de gene
US10360161B2 (en) 2017-03-29 2019-07-23 International Business Machines Corporation Cable lock with confidential data protection
GB201705765D0 (en) 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd HBV vaccine
WO2018199338A1 (ja) 2017-04-27 2018-11-01 国立大学法人広島大学 Ｂ型肝炎治療用核酸分子
EP3607968A4 (en) 2017-06-05 2021-03-31 Beacle Inc. VIRAL-TYPE PARTICLES INTENDED FOR USE TO INDUCE AN IMMUNE RESPONSE AGAINST HBV
US11040033B2 (en) 2017-08-22 2021-06-22 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2019051257A2 (en) 2017-09-11 2019-03-14 Arbutus Biopharma Corporation METHODS OF TREATING HEPATITIS B TYPE INFECTIONS
US11389532B2 (en) 2017-11-16 2022-07-19 University Of Washington Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV PreS1 and/or PreS2, and/or s-HBsAg regions of the HBV envelope protein
US10796029B2 (en) 2017-11-30 2020-10-06 International Business Machines Corporation Software controlled port locking mechanisms
SG11202005709QA (en) 2017-12-19 2020-07-29 Janssen Sciences Ireland Unlimited Co Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
CA3086327A1 (en) 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
KR20200100745A (ko) 2017-12-19 2020-08-26 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물
US11021692B2 (en) * 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
MA53858A (fr) 2018-10-08 2021-09-15 Janssen Pharmaceuticals Inc Réplicons à base d'alphavirus pour l'administration d'agents biothérapeutiques
JP2022521155A (ja) 2019-02-07 2022-04-06 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬
JP2022536945A (ja) 2019-06-18 2022-08-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ
AU2020297008A1 (en) 2019-06-18 2022-02-17 Janssen Sciences Ireland Unlimited Company Combination of hepatitis B virus (HBV) vaccines and HBV-targeting RNAi
CA3188801A1 (en) 2020-07-08 2022-01-13 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法

Also Published As

Publication number Publication date
US20210269778A1 (en) 2021-09-02
US20190185828A1 (en) 2019-06-20
US11021692B2 (en) 2021-06-01
US11725194B2 (en) 2023-08-15

Similar Documents

Publication Publication Date Title
EA202091513A1 (ru) Вакцины против вируса гепатита b (hbv) и их применение
MX2020011802A (es) Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas.
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
CO2021004188A2 (es) Vacuna contra el virus de la peste porcina africana
PH12019550220A1 (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
CY1124254T1 (el) Μεθοδοι και συνθεσεις για την προκληση προστατευτικης ανοσιας εναντι λοιμωξης ιου της ανθρωπινης ανοσοανεπαρκειας
EA202090759A2 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
EA201892735A1 (ru) Состав вакцины против hiv
EA201890042A1 (ru) Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
BR112022027038A2 (pt) Vacinas de replicon de rna contra hbv
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
PH12018502436A1 (en) Multivalent vaccines major swine viral diseases
BR112018007121A2 (pt) anticorpo ou antígeno de ligação ao fragmento do mesmo, anticorpo humanizado ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o anticorpo ou um antígeno de ligação ao fragmento do mesmo, composição farmacêutica, uso do anticorpo ou um antígeno de ligação ao fragmento do mesmo e método para prevenir ou tratar infecção hbv ou uma doença associada com a infecção hbv
MX2017011732A (es) Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.
BR112022003474A2 (pt) Vacinas do vírus da hepatite b
AR113961A1 (es) Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas
EA202191862A3 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
Golshani et al. A RECOMBINANT SUBUNIT VACCINE BASED ON THE L7/L12 AND TOMP31 PROTEINS INDUCES PROTECTION AGAINST BRUCELLA INFECTION IN BALB/C MICE
AR105134A1 (es) Vacunas contra la influenza con coincidencia antigénica
TH1601000429A (th) การเร่งความเร็วในการตอบสนองทางภูมิคุ้มกันที่ไวรัสพาหะเหนี่ยวนำ ให้เกิดขึ้นในสัตว์ปีก
TH167679B (th) โมเลกุลกรดนิวคลีอิกซึ่งเข้ารหัสโปรตีนแกนกลางไวรัสตับอักเสบชนิดบี และโปรตีนแอนติเจนพื้นผิวและวัคซีนซึ่งประกอบรวมด้วยสิ่งเดียวกัน